Polen Capital Management’s Ascendis Pharma A/S ASND Stock Holding History

Polen Capital Management’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-1,812	Closed	-$414K	–	224
2026 Q1	$414K	Buy	1,812 +601	+50%	+$135K	﹤0.01%	186
2025 Q4	$258K	Sell	1,211 -1,555	-56%	-$321K	﹤0.01%	216
2025 Q3	$550K	Buy	2,766 +47	+2%	+$8.77K	﹤0.01%	178
2025 Q2	$469K	Buy	+2,719	New	+$443K	﹤0.01%	198

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $30.6B AUM 61.81% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $63.1B AUM 35.51% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Massachusetts Financial Services Boston, Massachusetts $315B AUM 27.84% 1-Year Est. Return

Polen Capital Management's ASND Position: Q2 2026 in Review

Polen Capital Management sold out of Ascendis Pharma A/S (ASND) in Q2 2026, closing a stake of 1,812 shares — an estimated $414K sold.

Polen Capital Management first reported a position in ASND in Q2 2025 and held it in 4 quarters. The position peaked at $550K in Q3 2025. 311 funds tracked by Wall St. Rank hold ASND as of Q2 2026.

Polen Capital Management reported no remaining Ascendis Pharma A/S position as of Q2 2026 after selling out during the quarter.
Polen Capital Management sold 1,812 Ascendis Pharma A/S shares in Q2 2026, an estimated $414K.
Polen Capital Management first reported a position in Ascendis Pharma A/S in Q2 2025 and held it in 4 quarters.
Polen Capital Management's Ascendis Pharma A/S position peaked at $550K in Q3 2025.
311 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2026.

Based on Polen Capital Management's 13F filing for Q2 2026, filed 4 Aug 2026.